Development Management

Michael Hepperle, Ph.D.

1-619-***-**** ***************@*****.***

LinkedIn: www.linkedin.com/in/michaelhepperle

**** *** ******, ***. ****, San Diego, CA 92101

SUMMARY

** ***** ********** **** in small molecule research with two postdoctoral years in

pharmaceutical companies

Experienced drug discovery leader with a proven record . Delivered 9 preclinical / 3 clinical

candidates and provided excellent leadership and expert knowledge in medicinal chemistry

and in its application to drug discovery

Team delivered over the last 2.5 years five new projects and six preclinical candidates

and supported two phase I compounds in various disease areas such as inflammation,

immunomodulation, pain and respiratory

Currently heading a team of 38 scientists including 6 PhDs, 11 chemical engineers and

two associate directors

Chaired a cross-functional kinase working group bringing together scientists from structural

biology, pharmacology, lead discovery and computational, high -throughput, and medicinal

chemistry

Prioritized and tracked projects; balanced risk based portfolio in the global discovery

leadership team

Allocated and supervised internal and external FTEs

Set up network of vendors, experts and solution providers

Other key expertise and personal attributes:

o Successfully applied structure based and computer aided drug design

o Used tools such as virtual, pharmacophore and fragment screening

o Presented discovery achievements to Boards of Directors, due diligence teams and

review panels

o Demonstrated change agility and versatility during M&A, rightsizing and site closures

o Hired, developed and mentored scientists

o Managed geographically dispersed teams

o Culturally adoptable, fit for difficult positions, bridge builder

o 27 publications and 23 patents

o US citizen, bilingual: English, German

EMPLOYMENT HISTORY

Nycomed: a Takeda Company (since October 2011), Constance, Germany

Nycomed GmbH, Constance, Germany

Director, Head of Medicinal Chemistry and Drugability Properties, 2009 – 12/2012

Member of the Global Discovery Leadership Team (GDLT) for the purpose of defining portfolio

strategies, managing the discovery pipeline and delegating roles and responsibilities

Scout targets with emphasis on therapeutical areas such as respiratory, autoimmune,

inflammatory, metabolic and pain

Lead all aspects of Medicinal Chemistry including target selection, dynamic resourcing,

portfolio and pipeline risk balancing and collaborate with our international chemistry group in

India

In charge of additional discovery functions, namely eADME and Compound Management

1

Delivered 2 preclinical candidates and transitioned 6 projects into lead optimization and 6

projects into lead discovery in 2011

Phenomix Corporation, San Diego, CA

Director, Medicinal Chemistry, 2005 –2009

Guided HCV protease inhibitor program from conception into the clinic in 2.5 years

Supported non-clinical efforts for DPP-4 inhibitor dutogliptin during Phase III

Handled all aspects of Medicinal Chemistry, compound evaluation, compound advancement,

clinical candidate selection, patent searches and composition of matter assurance

Directed Medicinal Chemistry drug discovery efforts targeting serine and metallo -proteases,

NS5b polymerase and kinases

Supervised internal and external teams of up to 27 medicinal and process chemists

Started a new kinase and polymerase programs

Millennium Pharmaceuticals, Cambridge, MA

Senior Scientist II, 2005

Senior Scientist I, 2002 –2005

Inflammation Chemistry Project Team Leader

Directed Medicinal Chemistry drug discovery efforts for Millenn ium’s inflammation kinase

programs

Supervised a matrix medicinal chemistry team of up to fourteen chemists

Chaired a cross functional working group focusing on the development of kinase inhibitors as

targets in oncology and inflammation with participation from Lead Discovery, Structural

Biology, Pharmacology and Medicinal, Computational and High Throughput Chemistry

Supervised a medicinal chemistry team of ten chemists

Produced a clinical candidate for the IKK2 inhibitor program (Phase I)

Identified two development candidates

Played key roles in advancing NF- B pathway inhibitors in Inflammation programs such as

rheumatoid arthritis and asthma into preclinical development and in identifying backup

compounds with improved potency, metabolic, pharmacokinetic and toxicity profiles

Interacted and devised strategies on a daily basis with in vitro and in vivo Pharmacology,

Drug Disposition, Molecular and Investigative Toxicology a nd Process Research departments

Assisted the Legal department to secure MPI’s intellectual property through patent

applications

Supported and expanded the Oncology Chemistry franchise as it related to NF - B pathway

inhibitors

Collaborated with Aventis in the Inflammation and Oncology franchises

Pharmacia Corporation/ Searle Pharmaceuticals, St. Louis, MO

Specialist, 1998 – 2002

Group Leader, Arthritis and Inflammation

Led a group of two chemists

Generated a clinical candidate for the P38 kinase inhibitor program (Phase II)

Directed chemistry support for pre-clinical studies and led back-up efforts

2

Schering-Plough Corporation, Kenilworth, NJ

Postdoctoral Process Research Associate, 1997

Designed, implemented and performed new syntheses for two developmental drugs as a

member of the process chemistry group

Hoechst Marion Roussel, Lawrence, KS

Postdoctoral Discovery Research Associate, 1996

W orked independently for an immunosuppressant program and produced four compounds

that were chosen for further development

Co-inventor on four patents

EDUCATION

Ph.D., Medicinal Chemistry, University of Kansas, School of Pharmacy, 1995

Isolation, identification, preparation, conformational aspects and biological activities of Taxanes

Advisor : Professor Gunda Georg

M.S., Medicinal Chemistry, University of Kansas, School of Pharmacy, 1992

Medicinal Chemistry of Taxol

Advisor : Professor Gunda Georg

Registered Pharmacist, State Board of Baden-Wuerttemberg, Stuttgart, Germany,

1988

Pharmacy Degree, University of Heidelberg, Germany, 1987

RELATED CREDENTIALS

Conferences 2011

o Emerging Pharma Markets Summit, Cannes, France, March 21-23

o Europe Summit Next Generation Pharmaceuticals, Bremen, Germany, April 5-7

NGP Drug Development Summit, Faro, Portugal, November 29 – December 1

o

Change Management Training

o Initiating and Implementing Change Programs, Dr. Rudi Potocnik, March 29-31, 2010

o Separation Culture, Dr. Laurenz Andrzejewski, April 2010

References available upon request

Patent and publication list available upon request

3

Contact this candidate